129 related articles for article (PubMed ID: 1599804)
21. Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.
Blomgren H; Edsmyr F; Esposti PL; Näslund I
Biomed Pharmacother; 1984; 38(3):143-9. PubMed ID: 6383491
[TBL] [Abstract][Full Text] [Related]
22. [Combination therapy of chronic myelogenous leukemia with busulfan and bestatin].
Uzuka Y; Saito Y
Gan To Kagaku Ryoho; 1991 Apr; 18(4):571-8. PubMed ID: 2012399
[TBL] [Abstract][Full Text] [Related]
23. [Randomized controlled trial of postoperative adjuvant chemotherapy with bestatin for gastric cancer].
Tanaka T; Oka T; Hashimoto I
Gan To Kagaku Ryoho; 1985 Jan; 12(1):125-33. PubMed ID: 3917653
[TBL] [Abstract][Full Text] [Related]
24. [Clinical studies of bestatin on genitourinary cancer].
Ichikawa T; Hirokawa I; Ishihara Y
Jpn J Antibiot; 1985 Jan; 38(1):166-78. PubMed ID: 3989976
[TBL] [Abstract][Full Text] [Related]
25. Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.
Abe F; Schneider M; Black PL; Talmadge JE
Cancer Immunol Immunother; 1989; 29(4):231-6. PubMed ID: 2752391
[TBL] [Abstract][Full Text] [Related]
26. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines.
Sekine K; Fujii H; Abe F
Leukemia; 1999 May; 13(5):729-34. PubMed ID: 10374877
[TBL] [Abstract][Full Text] [Related]
27. Bestatin treatment of myelodysplastic syndromes (MDS) and the effects of bestatin on hematopoiesis in MDS.
Uzuka Y; Saito Y
Acta Oncol; 1990; 29(6):803-7. PubMed ID: 2223153
[TBL] [Abstract][Full Text] [Related]
28. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy.
Kawa K; Konishi S; Tsujino G; Mabuchi S
Biomed Pharmacother; 1991; 45(2-3):113-6. PubMed ID: 1912366
[TBL] [Abstract][Full Text] [Related]
29. Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection.
Aoyagi K; Itoh N; Abe F; Abe S; Uchida K; Ishizuka M; Takeuchi T; Yamaguchi H
J Antibiot (Tokyo); 1992 Nov; 45(11):1778-84. PubMed ID: 1468987
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with bestatin in inoperable lung cancer. A randomized trial.
Takada M; Fukuoka M; Negoro S; Kusunoki Y; Matsui K; Masuda N; Sakai N; Ryu S; Takifuji N; Kudo S
Acta Oncol; 1990; 29(6):821-5. PubMed ID: 2223156
[TBL] [Abstract][Full Text] [Related]
31. [Double blind controlled study of ubenimex (Bestatin) against squamous cell lung cancer--a multicenter cooperative study].
Furuse K; Fukuoka M; Genka K; Kato H; Tsubura E; Ohta M; Nakai H; Kinuwaki E; Nakano M; Ishikawa S
Gan To Kagaku Ryoho; 1993 Jul; 20(9):1187-94. PubMed ID: 8333747
[TBL] [Abstract][Full Text] [Related]
32. [Bestatin-induced intravascular hemolysis in a patient with acute myelocytic leukemia].
Nakayama S; Yabe H; Ishikawa T; Nagai K
Rinsho Ketsueki; 1990 Jan; 31(1):66-9. PubMed ID: 2313907
[TBL] [Abstract][Full Text] [Related]
33. [Postoperative adjuvant immunochemotherapy with bestatin for stomach cancer. Randomized controlled trial: first report].
Yoshinaka K; Nakano A; Toge T; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1458-64. PubMed ID: 3925887
[TBL] [Abstract][Full Text] [Related]
34. Bestatin selectively suppresses the growth of leukemic stem/progenitor cells with BCR/ABL mRNA transcript in patients with chronic myelogeneous leukemia.
Fujisaki T; Otsuka T; Gondo H; Okamura T; Niho Y; Ohhinata A; Abe F
Int Immunopharmacol; 2003 Jun; 3(6):901-7. PubMed ID: 12781706
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro.
Saiki I; Murata J; Watanabe K; Fujii H; Abe F; Azuma I
Jpn J Cancer Res; 1989 Sep; 80(9):873-8. PubMed ID: 2513304
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin.
Uchibayashi T; Kunimi K; Yamamoto H; Koshida K
Int J Clin Pharmacol Ther; 1995 Aug; 33(8):465-8. PubMed ID: 8556228
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
[TBL] [Abstract][Full Text] [Related]
38. [Prospective randomized controlled study of bestatin in gastric cancer surgery].
Yoshinaka K; Tanaka T; Takagami S; Saeki T; Nishiyama M; Toge T; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1988 Mar; 15(3):493-8. PubMed ID: 3126708
[TBL] [Abstract][Full Text] [Related]
39. Prospective randomized controlled study on bestatin in resectable gastric cancer.
Niimoto M; Hattori T
Biomed Pharmacother; 1991; 45(2-3):121-4. PubMed ID: 1912368
[TBL] [Abstract][Full Text] [Related]
40. Effect of ubenimex (Bestatin) on the cell growth and phenotype of HL-60 and HL-60R cell lines: up-and down-regulation of CD13/aminopeptidase N.
Imamura N; Kimura A
Leuk Lymphoma; 2000 May; 37(5-6):663-7. PubMed ID: 11042531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
